Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates
May 06, 2024 08:00 ET
|
Krystal Biotech, Inc.
Net product revenue of $45.3 million in 1Q and $95.9 million since AugustFirst patient dosed in inhaled KB707 study for locally advanced or metastatic tumors of the lungReceived Fast Track...
Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
May 02, 2024 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, May 02, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new...
Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024
April 26, 2024 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, April 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter...
Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung
April 22, 2024 07:00 ET
|
Krystal Biotech, Inc.
• Received Fast Track Designations for both inhaled and intratumoral KB707 PITTSBURGH, April 22, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage...
Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting
April 04, 2024 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, April 04, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new...
Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference
February 28, 2024 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the...
Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
February 26, 2024 08:00 ET
|
Krystal Biotech, Inc.
• Net product revenue of $42.1M in 4Q and $50.7M for the year • New England Journal of Medicine publication of the use of B-VEC eyedrop formulation • Reached alignment with FDA to enable...
Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
February 20, 2024 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, will report its fourth quarter and full year 2023...
Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung
February 13, 2024 07:00 ET
|
Krystal Biotech, Inc.
• FDA clears IND and Phase 1 (KYANITE-1) clinical trial expected to be initiated in 1H 2024 PITTSBURGH, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a...
Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa
February 08, 2024 07:00 ET
|
Krystal Biotech, Inc.
• Initial clinical data suggest the potential of B-VEC to treat lesions in the eye of DEB patients and additional applications of Krystal’s HSV-1 platform to treat ocular diseases • Repeat...